HIGHLIGHTS
- who: Lotte C. Terpstra from the Department of Pulmonary Diseases, Northwest Clinics, Wilhelminalaan, JD Alkmaar, The Netherlands have published the research: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis, in the Journal: (JOURNAL)
- what: The study showed that OD continuous treatment of TIS was well tolerated, with no increase in tobramycin resistance or side effects as compared to earlier trials with the BID 28 days on-off treatment schedule . Cough and dyspnea were mentioned mostly during the study, which were reasons for study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.